×
About 1,703 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  645 results

Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma p...
https://doi.org/10.1530/ERC-21-0202
Endocrine-related Cancer; Haberbosch L, Maurer L et. al.

Jan 12th, 2022 - Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis. Mitotane, a derivative of the pesticide DDT, has been used successfully as first line chemotherapy since the 1960s, if maintained within a narrow therapeutic wind...

ASO Visual Abstract: Adrenocortical Carcinoma-The Value of Lymphadenectomy.
https://doi.org/10.1245/s10434-021-11175-8
Annals of Surgical Oncology; Tseng J, DiPeri T et. al.

Jan 8th, 2022 - ASO Visual Abstract: Adrenocortical Carcinoma-The Value of Lymphadenectomy.|2022|Tseng J,DiPeri T,Chen Y,Shouhed D,Ben-Shlomo A,|

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
https://clinicaltrials.gov/ct2/show/NCT01772004

Dec 20th, 2021 - This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all...

Identification of prognostic metabolic genes in adrenocortical carcinoma and establishm...
https://doi.org/10.1097/MD.0000000000027864
Medicine Chen Q, Ren Z et. al.

Dec 18th, 2021 - Adrenocortical carcinoma is an invasive malignancy with poor prognosis, high recurrence rate and limited therapeutic options. Therefore, it is necessary to establish an effective method to diagnose and evaluate the prognosis of patients, so as to ...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Dec 16th, 2021 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  12 results

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
https://clinicaltrials.gov/ct2/show/NCT01772004

Dec 20th, 2021 - This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Dec 16th, 2021 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
https://clinicaltrials.gov/ct2/show/NCT04373265

Oct 1st, 2021 - Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goal of this study is to assess the safety and efficacy of relacorilant when given in combination with pembrolizumab in patients with advanced adrenocortical carc...

Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
https://clinicaltrials.gov/ct2/show/NCT02324647

Sep 30th, 2021 - Rationale: Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical carcinoma...

German Adrenocortical Carcinoma Registry
https://clinicaltrials.gov/ct2/show/NCT00453674

Jun 4th, 2021 - Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of patients with adrenocortical cancer. The registration of as many patients as possible helps to collect data for the prognosis and prospects of success regard...

see more →

News  23 results

Neuroendocrine Tumors Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/959868

Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...

Innovation Fuels Breakthroughs for Rare Cancers
https://www.onclive.com/view/innovation-fuels-breakthroughs-for-rare-cancers

Jun 2nd, 2021 - Although there are only approximately 10,000 people in the United States living with von Hippel-Lindau (VHL) syndrome, nearly 3 dozen cancer institutes and hospitals throughout the nation have joined a network of specialized clinical centers for d...

Advanced HCC: What's Next?
https://www.onclive.com/view/advanced-hcc-whats-next

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...

The Benefits of Genetic Testing for Cancer Survivors
https://www.onclive.com/view/the-benefits-of-genetic-testing-for-cancer-survivors

Dec 5th, 2020 - Ellen T. Matloff, MS, CGC Certified genetic counselor and director of Cancer Genetic Counseling at Yale Cancer Center, New Haven, Connecticut Should the clinician discuss genetic options with cancer survivors? When should this information b...

Urine Screen as Part of Triple Test Improves ID of Adrenal Cancer
https://www.medscape.com/viewarticle/934790

Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...

see more →